Immutep Limited (ASX: IMM) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Immutep Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Immutep Limited (ASX: IMM)
Latest News
Share Gainers
Why 29Metals, Immutep, Insignia, and Perenti shares are pushing higher today
Share Gainers
Why Immutep, Kingsgate, Netwealth, and Ora Banda shares are storming higher
Healthcare Shares
Why is this ASX healthcare stock rocketing 25% on Friday?
Share Gainers
Why Coronado Global, EML, Immutep, and Lendlease shares are storming higher
Healthcare Shares
'Obvious buying opportunity': Top broker says beaten-up ASX All Ords stock has 253% upside
Share Fallers
Why Abacus, Bannerman Energy, Immutep, and Pilbara Minerals shares are falling today
Share Fallers
Why APA Group, Immutep, NAB, and Immutep shares are sinking
Healthcare Shares
Why did this ASX healthcare stock just crash 47%?
Broker Notes
This speculative ASX stock could almost double in value
Share Fallers
Why Brainchip, Immutep, Liontown, and Xero shares are tumbling today
Broker Notes
These ASX stocks could rise 30% to 85%
Share Gainers
Why Argosy Minerals, Immutep, Pointsbet, and Regis Resources shares are racing higher
Frequently Asked Questions
-
No, Immutep does not pay dividends at this time.
-
Immutep Ltd listed on the ASX on 23 June 1988.
IMM ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Immutep Limited
Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.
